Penn State recently released some results from the ongoing PATH study regarding users’ dependency on e-cigarettes and regular cigarettes. To see the current results, as well as future plans for the PATH...
In a new study, researchers aimed to determine the effects of a diabetes drug added to clozapine or olanzapine treatment for schizophrenia. To see the results, including how the drug affected...
Aristada recently received approval from the US Food and Drug Administration for a new and shorter dosing regimen, providing more options to patients and health care providers.
Inappropriate antibiotic use is a contributing factor to rising antibiotic resistance rates. A recent study examined trends in antibiotic prescriptions for acute respiratory tract infections to determine if...
In a large-scale meta-analysis, researchers analyzed the prevalence and incidence of cardiovascular diseases and cardiovascular-related death in patients with severe mental illness and the general...
In the year following a new psychosis diagnosis, the death rate for young people is 24 times higher than for young people without psychosis, according to a new study published online in Schizophrenia...
An exaggerated emotional brain response to nonthreatening, nonemotional cues at age 14 predicted the onset of psychosis symptoms within the next 2 years.
RP5063, a dopamine serotonin stabilizer, was associated with symptom improvement in adults with acute exacerbation of schizophrenia or schizoaffective disorder.
